Issue 16 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

31

No.

16

April 22, 2005Apr 22, 2005

Free

DOWNLOAD THE PDF

SWOG, NCI Canada halt two large trials of Iressa for non-small cell lung cancer.

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

Paulette Gray named director of NCI Division of Extramural Activities.

Recent Issues

Volume 52 | Issue 17 - May 01, 2026

Volume 52 | Issue 16 - April 24, 2026

Volume 52 | Issue 15 - April 17, 2026

Volume 52 | Issue 14 - April 10, 2026

Volume 52 | Issue 13 - April 03, 2026

Volume 52 | Issue 12 - March 27, 2026